Ertapenem, the first of a new group of carbapenems

Open Access
Publisher Website
Google Scholar
Abstract
β-Lactam antimicrobials have been widely prescribed to treat serious infections for nearly 60 years owing to their excellent efficacy, safety and tolerability profiles. Among the many different structurally distinct classes of β-lactams, the carbapenem class, while sharing these general β-lactam features, is regarded as the class that is most potent and that has the widest spectrum of antimicrobial activity. At the time that the carbapenems were last reviewed in this journal,1 imipenem and meropenem were the only carbapenems that were available in the majority of the world. Since then ertapenem (formerly MK-0826), a new long-acting, parenteral carbapenem (Figure 1), has received regulatory approval in the United States (November 2001) and the European Union (April 2002).

This publication has 0 references indexed in Scilit: